102P - Characterization of PD-L1 expression and assessment of association with tumor histology and gene expression status in pretreatment non-small cell lu...

Date 28 March 2014
Event ELCC 2014
Session Lunch and poster display session
Topics Non-Small-Cell Lung Cancer, Metastatic
Pathology/Molecular Biology
Presenter Christopher Harbison
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors C.T. Harbison1, J.F. Kurland2, C.E. Horak2, J.P. Cogswell2, H..D. Inzunza2, X. Hu2, X. Han2, J.F. Novotny2, J.S. Simon2, M.N. Jure-Kunkel2
  • 1Oncology, Bristol-Myers Squibb, 08540 - Princeton/US
  • 2Oncology, Bristol-Myers Squibb, Princeton/US

Abstract

Immunohistochemistry (IHC) analysis suggested an association between pretreatment tumor programmed death ligand 1 (PD-L1) expression and response to the human IgG4 PD-1 immune checkpoint inhibitor antibody nivolumab (Nivo) (Grosso ASCO 2013 abstract 3016). Associating PD-L1 expression with gene profiles, mutational status, or patient (pt) characteristics may inform which pts may be more likely to benefit from Nivo therapy.